Factor Xa Levels in Patients Receiving Prophylactic Enoxaparin Sodium in the Intensive Care Unit of an Academic Hospital
| Autor: | Daren Calleemalay, Helen Perrie, Shahed Omar, Mayank M Baloo, Juan Scribante |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Bilirubin
Serum albumin Critical Care and Intensive Care Medicine law.invention Venous thromboembolism (VTE) prophylaxis chemistry.chemical_compound law Medicine In patient Anesthesia Intensive care unit Enoxaparin Brief Research Communications biology business.industry Study methodology Pharmacokinetics–pharmacodynamics chemistry biology.protein business Body mass index Venous thromboembolism Enoxaparin sodium Prevention of VTE medicine.drug |
| Zdroj: | Indian Journal of Critical Care Medicine : Peer-reviewed, Official Publication of Indian Society of Critical Care Medicine |
| ISSN: | 0972-5229 |
| Popis: | Background: The aim of this study was to determine the anti-factor Xa levels in patients receiving enoxaparin sodium for venous thromboembolism prophylaxis in the intensive care unit (ICU). Patients and methods: Using a cross-sectional study methodology, 73 ICU patients receiving 40 mg enoxaparin sodium daily were enrolled in this study. Anti-factor Xa levels were measured following the second dose. Prophylactic and subprophylactic groups of patients were compared for age, sex, weight, body mass index, total bilirubin, serum albumin, and APACHE II score. Results: Anti-factor Xa levels were prophylactic (0.2–0.6 IU/mL) in 44 (60.3%) patients and subprophylactic ( |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|